A Potent Zwitterionic Inhibitor of KHK
Resmetirom (REZDIFFRA™) became the first FDA-approved treatment for NASH on Mar. 14th, 2024. This oral, liver-targeting THR-β-selective agonist, discovered at Roche Nutley, was highlighted as Molecule of the Month in Dec. 2022 and is a 2023 Molecule of the Year nominee.
Reference News
Resmetirom (REZDIFFRA™) became the first FDA-approved treatment for NASH on Mar. 14th, 2024. This oral, liver-targeting THR-β-selective agonist, discovered at Roche Nutley, was highlighted as Molecule of the Month in Dec. 2022 and is a 2023 Molecule of the Year nominee.
Resmetirom (REZDIFFRA™) became the first FDA-approved treatment for NASH on Mar. 14th, 2024. This oral, liver-targeting THR-β-selective agonist, originally discovered at Roche Nutley, was first highlighted in Dec. 2022 and is now a 2023 Molecule of the Year nominee.
Resmetirom (REZDIFFRA™) became the first FDA-approved treatment for NASH on Mar. 14th, 2024, marking a historic milestone in liver drug discovery.